Doctor prescribes a walk on the beach: nature therapy tested for stress relief
NCT ID NCT06622629
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a 5-week nature-based therapy program—featuring guided walks and mindfulness in a coastal urban park—could improve stress resilience and quality of life in 100 healthy adults. Participants attended three 60-minute sessions per week and were followed for another 5 weeks. The researchers measured changes in stress biomarkers, emotional well-being, and health-related quality of life to see if time in nature can boost overall health.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Nature-based therapy (guided walks and mindfulness in a coastal urban park)
- What this could lead to
- If it works, this could support adding nature-based therapy to public health programs for stress reduction and well-being.
- What could go wrong
- This is a small, completed study in healthy volunteers, not a treatment for a disease. Results may not apply to other populations or settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
100 people
The number who actually took part.
- Started
-
Sep 2024
- Finished
-
Oct 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults \>=18 years * Smartphone users Exclusion Criteria: * Acute contraindications \- Malignant hypertension * Contraindications or differential diagnosis * Severe respiratory or pulmonary disease (COPD, severe asthma, emphysema) * Arteriosclerotic incident (e.g., myocardial infarction) 6 months previous the study starting * Heart failure * Uncontrolled metabolic diseases (e.g., diabetes mellitus) * Diagnosis or treatment of a malignant disease \< 3 years ago * Chronic immunological diseases (e.g., rheumatoid arthritis) * Orthopedic conditions that prevent participation in excursions * Factors that prevent or hinder participation in the intervention program * Alcohol or substance abuse (except nicotine) * Pregnancy * Insufficient knowledge of Spanish or Catalan (written and spoken/questionnaires) * Factors that prevent self-management * Moderate to severe depression (score \< 13 points on the WHO-5) * Other untreated severe psychiatric illnesses (e.g., schizophrenia) * Taking certain medications * Use of weight loss supplements * Participation in another clinical intervention trial * Participation in therapeutic weight loss programs
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy participants are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ISGlobal
Barcelona, Barcelona, 08003, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Does it matter where you inject? scientists test Weight-Loss drug in arm, thigh, and belly
- New drug RO7830698 put to the test for COPD
- Three pill versions of one drug go head to head in the bloodstream
- Pfizer tests RSV vaccine aimed at older adults
- Radioactive tracer maps where a new drug goes in the body
- Radioactive tag lets scientists follow an experimental drug through the human body